OptiNose, Inc.

Equities

OPTN

US68404V1008

Pharmaceuticals

Market Closed - Nasdaq 04:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
1.48 USD 0.00% Intraday chart for OptiNose, Inc. -13.70% +14.73%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Lake Street Adjusts Price Target on OptiNose to $4 From $3, Maintains Buy Rating MT
Sector Update: Health Care Stocks Steady Premarket Monday MT
OptiNose Says US FDA Approves Xhance to Treat Chronic Rhinosinusitis MT
Optinose Says FDA Approves Xhance to Treat Chronic Rhinosinusitis DJ
OptiNose, Inc. Announces U.S. Food and Drug Administration Approved XHANCE (Fluticasone Propionate) Nasal Spray for the Treatment of Chronic Rhinosinusitis Without Nasal Polyps in Patients 18 Years of Age and Older CI
Optinose, Inc. Provides Update on Hikma Manufacturing Agreement CI
HC Wainwright Initiates OptiNose With Buy Rating, $5 Price Target MT
Transcript : OptiNose, Inc., Q4 2023 Earnings Call, Mar 07, 2024
Earnings Flash (OPTN) OPTINOSE Posts Q4 Revenue $19.9M MT
OptiNose, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
OptiNose, Inc. Provides Earnings Guidance for the First Quarter of 2024 CI
OptiNose, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
North American Morning Briefing : Powell Still in -2- DJ
Optinose Announces the Publication of ReOpen Phase 3 Clinical Trial Program Evaluating XHANCE in the Journal of Allergy and Clinical Immunology CI
OptiNose, Inc.(NasdaqGS:OPTN) dropped from NASDAQ Biotechnology Index CI
Optinose Shares Slide Premarket as FDA Extends Xhance Review DJ
OptiNose Says US FDA Extended Review of Supplemental New Drug Application for Xhance in Chronic Rhinosinusitis MT
Optinose Announces 3-Month Extension of FDA Review Period for the Supplemental New Drug Application for XHANCE CI
Transcript : OptiNose, Inc., Q3 2023 Earnings Call, Nov 09, 2023
Earnings Flash (OPTN) OPTINOSE Posts Q3 Revenue $19.8M MT
OptiNose, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
OptiNose, Inc. Revises Revenue Guidance for the Full Year of 2023 CI
Lake Street Initiates OptiNose at Buy Rating With $3 Price Target MT
OptiNose Files $200 Million Mixed Shelf MT
OptiNose Raises Full-Year 2023 Xhance Net Revenue Outlook MT
Chart OptiNose, Inc.
More charts
OptiNose, Inc. is a specialty pharmaceutical company focused on the development and commercialization of products for patients treated by ear, nose and throat (ENT) and allergy specialists. Its first commercial product, XHANCE (fluticasone propionate) nasal spray, 93 microgram, is a therapeutic utilizing its exhalation Delivery System (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps. XHANCE combines the EDS with a liquid formulation of fluticasone propionate, a corticosteroid. XHANCE is designed to deliver medication into the high and deep regions of the nasal passages where both nasal polyps and inflamed and swollen membranes can obstruct normal sinus ventilation and drainage. Its powder EDS, which is the EDS used in its ONZETRA Xsail consists of a reusable device body incorporating a flexible mouthpiece to adjust to individual anatomic variations, and a white button piercing assembly to pierce the medication capsule.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.48 USD
Average target price
3.75 USD
Spread / Average Target
+153.38%
Consensus
  1. Stock
  2. Equities
  3. Stock OptiNose, Inc. - Nasdaq
  4. News OptiNose, Inc.
  5. Jefferies Assumes OptiNose at Buy with $5 Price Target